Chinese expert consensus on sequential surgery following conversion therapy based on combination of immune checkpoint inhibitors and antiangiogenic targeted drugs for advanced hepatocellular carcinoma (2024 edition).
Tang H, Zhang W, Cao J, Cao Y, Bi X, Zhao H, Zhang Z, Liu Z, Wan T, Lang R, Sun W, Du S, Yang Y, Lu Y, Zeng D, Wu J, Duan B, Lin D, Li F, Meng Q, Zhou J, Xing B, Tian X, Zhu J, Gao J, Hao C, Wang Z, Duan F, Wang Z, Wang M, Liang B, Chen Y, Xu Y, Li K, Li C, Hu M, Wang Z, Cai S, Ji W, Xia N, Zheng W, Wang H, Li G, Zhu Z, Huang Z, Zhang W, Tao K, Liang J, Zhang K, Dai C, Li J, Qiu Q, Guo Y, Wu L, Ding W, Zhu Z, Gu W, Cao J, Wang Z, Tian L, Ding H, Li G, Zeng Y, Wang K, Yang N, Jin H, Chen Y, Yang Y, Xiu D, Yan M, Wang X, Han Q, Jiao S, Tan G, Wang J, Liu L, Song J, Liao J, Zhao H, Li P, Song T, Wang Z, Yuan J, Hu B, Yuan Y, Zhang M, Sun S, Zhang J, Wang W, Wen T, Yang J, Du X, Peng T, Xia F, Liu Z, Niu W, Liang P, Xu J, Zhao X, Zhu M, Wang H, Kuang M, Shen S, Cui X, Zhou J, Liu R, Sun H, Fan J, Chen X, Zhou J, Cai J, Lu S; Professional Committee for Prevention and Control of Hepatobiliary and Pancreatic Diseases of Chinese Preventive Medicine Association; Chinese Society of Liver Cancer, Liver Study Group of Surgery Committee of Beijing Medical Association; Editorial Board of the Chinese Journal of Hepatobiliary Surgery.
Tang H, et al.
Biosci Trends. 2025 Jan 14;18(6):505-524. doi: 10.5582/bst.2024.01394. Epub 2024 Dec 25.
Biosci Trends. 2025.
PMID: 39721704
Free article.
